An argument for clarifying the nomenclature
Parkinson’s disease (PD) was named in 1872 for British surgeon James Parkinson, who first described “the shaking palsy” more than a half-century earlier. Ever since then, a murky and imprecise lexicon has developed around a wide variety of conditions with characteristics that overlap with, are related to, or are differentiated from PD.
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
This language, particularly the term “atypical Parkinsonism,” can cause confusion for patients, families and medical teams and create stigma for individuals receiving a diagnosis. That’s why Cleveland Clinic movement disorders specialist Junaid H. Siddiqui, MD, and Lawrence I. Golbe, MD, Emeritus Professor of Neurology at Rutgers Robert Wood Johnson Medical School, are suggesting updates to terms pertaining to these conditions.
Their proposal, Time to retire the term “atypical Parkinsonism,” was published in Parkinsonism and Related Disorders.
In their, article the authors make the case for:
"The inconsistent and imprecise use of the term 'Parkinsonism' has created unnecessary confusion for patients, clinicians and researchers,” Dr. Siddiqui explains. “In addition, we have seen that the designation 'atypical Parkinsonism' can often feel discouraging to patients and create a sense of 'otherness.’ Refinements to the terminology can eliminate these issues and resolve problems of logic that beset the existing language.”
Currently, three major entities are characterized by Parkinsonism, a syndrome of bradykinesia with rigidity, tremor or both:
Advertisement
Under their proposed nomenclature, “secondary Parkinsonian disorders” would continue to be used for mostly non-degenerative Parkinsonian disorders.
“Parkinsonism,” however, calls for well-considered usage, the authors write. The term is often employed to describe both a clinical phenotype and specific diseases, which is confusing.
They suggest Parkinsonisms (plural) should be retired and that Parkinsonism be used only as the name for the phenotype.
“Parkinsonism was designed to be just a phenotype description,” says Dr. Siddiqui. “Unfortunately, even movement disorder neurologists tend to use it loosely to refer to the Parkinson-like disorders or even PD, thus adding to confusion when patients ask if they have parkinsonism or Parkinson's disease. Also, just like water or furniture, parkinsonism is a mass noun. There is no need to use the plural. Just as we say 'bodies of water' but we do not say 'waters' or we 'pieces of furniture' but we not 'furnitures,’ we should not be saying ‘parkinsonisms.’”
They also propose replacing “atypical Parkinsonism” and “Parkinson-plus syndrome” with “Parkinson-like disorders” to underscore and clarify that these conditions are not forms of PD. Parkinson-like disorders would include MSA, DLB, PSP and CBD.
“Atypical Parkinsonism” may connote, for some, lack of treatability or poor prognosis, the authors note, which can cause distress for patients. And “Parkinson-plus syndrome” erroneously implies these diseases are forms of PD.
The name “Parkinson-like disorders” carries no such connotations.
Advertisement
While changing medical nomenclature is never an easy task, progress begins with conversations, says Dr. Siddiqui.
“We can begin to build momentum by consistently using and promoting updated terminology in clinical practice and teaching, and by including the topic in professional discussions,” he says. “Social platforms such as LinkedIn provide a space to raise awareness. Eventually, we may be able to approach organizations such as the Movement Disorder Society to provide an avenue for broader adoption. Change may be slow, but it starts with each of us taking the initiative to lead by example."
Advertisement
Advertisement
An expert talks through the benefits, limits and unresolved questions of an evolving technology
Recommendations on identifying and managing neurodevelopmental and related challenges
Phase 2 trials investigate sitagliptin and methimazole as adjuvant therapies
Aim is for use with clinician oversight to make screening safer and more efficient
Rapid innovation is shaping the deep brain stimulation landscape
Study shows short-term behavioral training can yield objective and subjective gains
How we’re efficiently educating patients and care partners about treatment goals, logistics, risks and benefits
An expert’s take on evolving challenges, treatments and responsibilities through early adulthood